Mindcure Completes Beta Testing, Launches PsyCollage

Mind Cure Health (CSE: MCUR) has completed the beta testing phase for its proprietary bioinformatics platform. Referred to as PsyCollage, the tool has been developed to drive decision making for drug lead optimization while also assisting in the discovery of target receptors.

The completion of the beta test marks the achievement of the firms first quarter testing milestone for the technology. The platform is being developed by the company as a means of product discovery, with the development being led by Chief Scientific Officer Dr Ryan Hartwell.

The technology works by using predicative correlative statistical analytics of documented research within the field of psychedelics. The analytics is capable of dealing with biological data with large and complex data sets, with the platform evolving into a resource for discovery and analysis of target receptors, methods, and historical clinical data trial.

Following initial beta testing, the technology has lead to Mind Cure identifying a number of priority indications, including cluster headaches, neuropathic pain, traumatic brain injury and migraines.

“The PsyCollage platform was developed to help MINDCURE accelerate research and planning to identify the therapeutic potential of psychedelic compounds and inform our priority research programs. With this strategic focus, we’re reinforcing our commitment to accelerating research to solve how the world addresses pain and suffering, and substantiating our role as leaders in psychedelic science.”

Kelsey Ramsden, President & CEO

Additional use cases and commercialization scenarios for PsyCollage are currently being evaluated by the company as well, with the platform already having been deployed for product discovery and lead optimization.

Mind Cure Health last traded at $0.63 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why $50 Silver, $4000 Gold Might Be Closer Than Anyone Thinks | Bradley Langille – GoGold Resources

Why Silver’s True Price Could Be Much Higher | Joaquín Marias – Argenta Silver

Gold Enters A ‘Stronger For Longer’ Phase | Richard Young – i-80 Gold

Recommended

Emerita Resources Intersects Further Mineralization At El Cura, Expanding Deposit

ESGold Sees ANT Survey Reveal Vertically Continuous System To 1,200 Metres Depth

Related News

Mind Cure Launches Product Sales Division

Mind Cure Health (CSE: MCUR) continued its constant roll of news this week, announcing this...

Thursday, February 18, 2021, 07:19:26 AM

Mind Cure Health Announces $3.0 Million Financing

Mind Cure Health (CSE: MCUR) this morning announced that it is conducting a non-brokered private...

Friday, November 13, 2020, 08:28:28 AM

Mind Cure Health Appoints Rob Hill To Board Of Directors

Mind Cure Health (CSE: MCUR) this morning announced the appointment of Rob Hill to the...

Monday, February 22, 2021, 09:12:53 AM

Mind Cure Closes $3.6 Million Oversubscribed Financing

Mind Cure Health (CSE: MCUR) reported midday today that it has closed its non-brokered private...

Thursday, November 19, 2020, 04:28:12 PM

Mind Cure Doubles Bought Deal Financing To $20 Million

Strong demand continues within the psychedelics space, with Mind Cure Health (CSE: MCUR) announcing earlier...

Friday, January 22, 2021, 02:07:33 PM